Cassava Sciences, Inc.
NASDAQ:SAVA
26.95 (USD) • At close November 8, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | Cassava Sciences, Inc. |
Symbool | SAVA |
Munteenheid | USD |
Prijs | 26.95 |
Beurswaarde | 1,292,958,590 |
Dividendpercentage | 0% |
52-weken bereik | 8.79 - 42.2 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Mr. Remi Barbier |
Website | https://www.cassavasciences.com |
An error occurred while fetching data.
Over Cassava Sciences, Inc.
Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)